Programmable Recombinases Hearing Loss
Seamless Therapeutics signed an exclusive license deal with Eli Lilly in January 2026. $1.12B total value. Lilly gets exclusive rights for hearing loss applications.
The tech: programmable recombinases that do large, precise DNA insertions. They don’t depend on the cell’s own DNA repair pathways. That’s the key difference from CRISPR-based approaches, where you’re at the mercy of HDR efficiency (which is terrible in post-mitotic cells like hair cells).
For STRC, this matters. Stereocilin coding sequence is 6kb+. Too big for a single AAV. Dual-AAV splitting works but comes with efficiency penalties (our model shows this clearly). Recombinases could theoretically insert the full-length gene in one shot. One vector, precise integration, no splitting.
The catch: not yet demonstrated in cochlea. Nobody’s shown this works in hair cells. The platform exists, the money exists, but cochlear proof-of-concept doesn’t exist yet.
Still, $1.12B is real money. Lilly isn’t guessing. They see the same thing we see: STRC is a huge unmet need with a clear molecular target.
Source: GlobalNewsWire, January 28, 2026.
Connections
- STRC Gene Therapy — recombinases as alternative to dual-AAV splitting
- Dual Vector AAV Strategy — the problem recombinases could bypass
- Alternative STRC Delivery Hypotheses — fits as another delivery approach
- STRC Mini-STRC Single-Vector Hypothesis — competing single-vector strategy